Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
The compound is currently in Phase 3 clinical trials with expected FDA approval in late 2026 to early 2027
Funding new research to support adjunctive therapies The lack of support and funding from the FDA and diabetes companies for adjunctive therapies is discouraging for many, which is why organizations like Breakthrough T1D play a key role in supporting innovative studies
(Cell Mol Gastroenterol Hepatol, 2016) reported the effect was lost in PepT1-knockout mice
The appropriate dose of selenium induces the appearance of oxidative stress in yeast cells
US$ 20.53
US$ 29.52
US$ 26.69
